Small nerve injury may be the trigger for early manifestation or faster progression of amyotrophic lateral sclerosis (ALS) motor symptoms in the presence of disease-associated genetic contributing factors, a study with rats suggests. The study, “Mutant SOD1 prevents normal functional recovery through enhanced glial activation and loss…

Researchers at Israel’s Ben-Gurion University (BGU) have developed an artificial intelligence (AI) platform that can help monitor and predict the course of amyotrophic lateral sclerosis (ALS). The tool was designed by Boaz Lerne, PhD, associate professor at BGU, and his colleagues, in order to help identify biomarkers associated with neurodegenerative…

People with mutations in the gene coding for tumor protein p73 (TP73) are at higher risk of developing amyotrophic lateral sclerosis (ALS), researchers report. Their study, “Loss of TP73 function contributes to amyotrophic lateral sclerosis pathogenesis,” was published online in bioRxiv. There’s no doubt that some genes…

High LDL cholesterol levels, also known as “bad cholesterol,” may contribute to the development of amyotrophic lateral sclerosis (ALS), researchers report. Their study, “Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis” was published in Annals of Neurology. Several lifestyle and other factors are thought to…

A potential therapy for amyotrophic lateral sclerosis (ALS) consisting of an antibody that reduces the abnormal accumulation of the TDP-43 protein improved cognitive and motor performance in mice, a study shows. The study, “Viral-mediated delivery of antibody targeting TAR DNA–binding protein 43 mitigates associated neuropathology,” was published in The…

A gene therapy designed to block the activity of SARM1 protein prevented the loss of axons ­­­­— long projections that connect nerve cells and transport information ­­­­— making the therapy a potential strategy to reduce the loss of peripheral nerves in several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), according to a mouse…

The loss of a key enzyme, called adenosine deaminase, in astrocytes ­­­­— the energy-supporting cells of neurons ­­­­— leads to a toxic accumulation of molecules that contributes to the death of motor neurons seen in amyotrophic lateral sclerosis (ALS), a study shows. The study, “Astrocyte adenosine deaminase loss increases…

A “new voice” for people who cannot verbally communicate, such as those living with amyotrophic lateral sclerosis (ALS) or recovering from stroke, is a step closer to becoming reality. Researchers from the Zuckerman Institute at Columbia University have developed a computer algorithm that can recognize a person’s thoughts as…

SIRION Biotech and Denali Therapeutics have signed a new licensing agreement to develop a new generation of adeno-associated virus (AAV) vectors, harmless viruses used as vehicles to deliver gene therapies, to allow therapies to reach into the central nervous system (CNS) of people  with amyotrophic lateral sclerosis (ALS). The…

An upcoming webinar will focus on the novel approach to clinical trial design in the Modifying Immune Response and Outcomes in ALS (MIROCALS) trial, which aims to break the current impasse in therapy development for amyotrophic lateral sclerosis (ALS). During the webinar, P. Nigel Leigh, a motor neuron disease…